| 000 | 01749 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514024737.0 | ||
| 264 | 0 | _c20020604 | |
| 008 | 200206s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1046/j.1365-2036.2002.01168.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuang, J-Q | |
| 245 | 0 | 0 |
_aAcid suppression in healthy subjects following lansoprazole or pantoprazole. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cMar 2002 |
||
| 300 |
_a425-33 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _a2-Pyridinylmethylsulfinylbenzimidazoles |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Ulcer Agents _xpharmacokinetics |
| 650 | 0 | 4 |
_aBenzimidazoles _xpharmacokinetics |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aGastric Acid _xmetabolism |
| 650 | 0 | 4 | _aGastric Acidity Determination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aLansoprazole |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMonitoring, Physiologic |
| 650 | 0 | 4 |
_aOmeprazole _xanalogs & derivatives |
| 650 | 0 | 4 | _aPantoprazole |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aSulfoxides _xpharmacokinetics |
| 700 | 1 | _aGoldwater, D R | |
| 700 | 1 | _aThomson, A B R | |
| 700 | 1 | _aAppelman, S A | |
| 700 | 1 | _aSridhar, S | |
| 700 | 1 | _aJames, C F | |
| 700 | 1 | _aChiu, Y-L | |
| 700 | 1 | _aPilmer, B L | |
| 700 | 1 | _aKeith, R G | |
| 700 | 1 | _aHunt, R H | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 16 _gno. 3 _gp. 425-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2036.2002.01168.x _zAvailable from publisher's website |
| 999 |
_c11783857 _d11783857 |
||